Stephen M. Ansell, MD. PhD. and Radhakrishnan Ramchandren, MD discuss the Zuma 1 trial on pretreated large cell lymphoma. The CAR T-cell treatment showed a 60% to 70% response rates and a 40% durable response rate (remaining in remission after a year).
